Allogene Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (16)

View All

Latest Posts

About This Stock More About This Stock
Short Interest Update - Monday, March 27
Article By: Bespoke Investment Group
Monday, March 27, 2023 3:24 PM EDT
Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today.
In this article: MSTR, BYND, MARA, CVNA, ALLO, DSGN
Read
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Article By: Benzinga
Sunday, October 10, 2021 6:00 PM EDT
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
In this article: LLY, CCXI, XENE, ATRA, CLSD, RGNX, ALLO, PRLD, FDMT, OTLK
Read
Week In Review: Week's China Life Science Investments Total $800 Million
Article By: ChinaBio® Today
Saturday, December 19, 2020 12:23 PM EDT
Harbour BioMed completed a $221 million Hong Kong IPO to continue its novel drug development. Singlera Genomics, a San Diego-Shanghai genomics testing company, closed a $150 million Series B financing from China investors.
In this article: HBM, PFE, SCLN, ABBV, ALLO, ADCT, BNTX, LEGN
Read
Allogene Jumps, Compugen Plunges Following Release Of Cancer Meeting Abstracts
Article By: The Fly
Thursday, May 14, 2020 1:08 PM EDT
Jefferies analyst Biren Amin raised his price target on Allogene Therapeutics to $45 from $37, while keeping a Buy rating on the shares.
In this article: INO, SGEN, EXEL, CGEN, MEIP, MGNX, ALLO
Read
All Posts

Latest Tweets for $ALLO

No tweets yet!

PARTNER HEADLINES